Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers

Presented on November 26, 2018

Quyen Luu, MD – Central Georgia Infectious Diseases Associates, Macon, GA
Barry Statner, MD, FRCPC, FIDSA – Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA
Robin H. Dretler, MD – Infectious Disease Specialists of Atlanta, P.C., Decatur, GA
H Barry Baker, MD, FACP – Infectious Disease Physicians, Miami, FL
Brian S. Metzger, MD, MPH – Austin Infectious Disease Consultants, Austin, TX
Thomas C Hardin, PharmD – Healix Infusion Therapy, Sugar Land, TX
Claudia P Schroeder, PharmD, PhD – Healix Infusion Therapy, Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc, Sugar Land, TX

View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.